-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
We maintain our 12-month target price at $19, which is 16.5x our 2027 EPS view of $1.15, a discount to the trading multiple of 18.1x since going public in 2023. We think this multiple is justified given the litigation overhang and limited visibility into KVUE's standalone performance (the company is no longer providing forward-looking guidance and hosting an analyst call) due to the pending acquisition by Kimberly-Clark (KMB), expected to close during Q2 2026. We increase our 2026 EPS estimate to $1.15 from $1.10 following this morning's Q1 earnings release. We maintain our 2027 EPS estimate at $1.15. Kenvue delivered a solid first quarter that demonstrated continued operational momentum. Net sales increased to $3,909M (+4.5% Y/Y) with organic growth of 0.7%. The performance suggests management's operational initiatives are gaining traction as the company approaches the transaction close. The transaction received shareholder approval in January 2026, and regulatory approvals are progressing.